Evaluating only Aileron Therapeutics’s profile at its peak — without knowing the outcome — the model ranked Founder chaos as the #1 likely cause. Documented cause: No market fit.
Key Events Timeline
FOUNDING
PRODUCT LAUNCH
CRISIS
SHUTDOWN
Full Analysis
Free · no account needed
Documented cause
Aileron Therapeutics spun out of Harvard to develop stapled peptides — a novel class of chemically modified drug candidates designed to target previously undruggable intracellular proteins. Its lead asset ALRN-6924 entered Phase 2 clinical trials for cancer indications. After disappointing efficacy results and the inability to demonstrate sufficient therapeutic benefit, the company dissolved its clinical programs and wound down operations in 2021.
Lesson
“Platform technology biotechs must achieve clinical proof-of-concept within 7 years or the science risks being overtaken by next-generation approaches before efficacy is demonstrated.”